Non-Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review

FANG Chenxi, SUN Liya, LIU Yan, XIAO Li, SUN Lin

Abstract

Diabetic kidney disease (DKD) is a common complication of diabetes mellitus and approximately 1/3 of diabetic patients may progress to DKD. A typical early clinical manifestation of DKD is microalbuminuria and patients may present with macroproteinuria accompanied by a decrease in renal function condition as the disease progresses. It is generally believed that the likelihood of a reversal of the disease is reduced after the development of macroproteinuria in patients with DKD, and that eventually some patients' condition may develop into end-stage renal disease (ESRD). Moreover, the thickening of the glomerular basement membrane, mesangial matrix expansion, Kimmelstiel-Wilson (K-W) nodules, and glomerulosclerosis in end-stage diabetes mellitus are typical pathologic changes of DKD. However, some DKD patients, especially those with type 2 diabetes mellitus (T2DM) combined with chronic kidney disease, may have diverse clinical manifestations, showing variations in disease progression and regression, and manifesting as non-classical types of DKD, such as normoalbuminuric DKD, proteinuria-reduced DKD, and DKD with rapid decline in renal function. In addition, the formation of crescents, a special pathological change, is observed in renal biopsy. However, this issue is currently under-recognized by clinicians and therefore deserves more attention. In order to improve clinicians' understanding of the presentations and pathological changes of non-classical DKD and the level of DKD prevention and treatment in China, we present a preliminary introduction to the clinical phenotypes and pathological changes of non-classical types of DKD in this paper by summarizing the findings of our prior studies as well as domestic and international literature.


Keywords: Diabetic kidney disease,  Albuminuria remission,  Normoalbuminuria,  Rapid decline in renal function,  Crescent,  Review

 

Full Text:

PDF


References


BONNER R， ALBAJRAMI O， HUDSPETH J， et al. Diabetic Kidney Disease. Prim Care，2020，47(4): 645–659. doi: 10.1016/j.pop.2020.08.004.

ZOU Y， ZHAO L， ZHANG J， et al. Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease. Ren Fail，2022，44(1): 562–570. doi: 10.1080/0886022x.2022.2056053.

JIN Q， LIU T， QIAO Y， et al. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front Immunol，2023，14: 1185317. doi: 10.3389/fimmu.2023.1185317.

YU J， LIU Y， LI H， et al. Pathophysiology of diabetic kidney disease and autophagy: a review. Medicine (Baltimore)，2023，102(30): e33965. doi: 10.1097/md.0000000000033965.

RAYEGO-MATEOS S， RODRIGUES-DIEZ R R， FERNANDEZ-FERNANDEZ B， et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int，2023，103(2): 282–296. doi: 10.1016/j.kint.2022.10.030.

TONNEIJCK L， MUSKIET M H， SMITS M M， et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol，2017，28(4): 1023–1039. doi: 10.1681/asn. 2016060666.

SELBY N M， TAAL M W. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab，2020，22(Suppl 1): 3–15. doi: 10.1111/dom.14007.

Chapter 2: Definition， identification， and prediction of CKD progression. Kidney Int Suppl (2011)， 2013， 3(1): 63−72. doi: 10.1038/kisup.2012.65.

American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care，2022，45(Suppl 1): S175–S184. doi: 10. 2337/dc22-S011.

OSHIMA M， SHIMIZU M， YAMANOUCHI M， et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol，2021，17(11): 740–750. doi: 10.1038/s41581-021-00462-y.

TERVAERT T W， MOOYAART A L， AMANN K， et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol，2010，21(4): 556–563. doi: 10.1681/asn.2010010010.

EADON M T， SCHWANTES-AN T H， PHILLIPS C L， et al. Kidney histopathology and prediction of kidney failure: a retrospective cohort study. Am J Kidney Dis，2020，76(3): 350–360. doi: 10.1053/j.ajkd.2019. 12.014.

SCHROERS J E， GILBERT A M， MCKENZIE P R， et al. Rapidly progressive crescentic diabetic nephropathy: two case reports. Intern Med J，2022，52(3): 479–484. doi: 10.1111/imj.15702.

MOGENSEN C E， CHRISTENSEN C K， VITTINGHUS E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes，1983，32 Suppl 2: 64–78. doi: 10.2337/diab.32.2. s64.

CHEN J， WANG X， HE Q， et al. YAP activation in renal proximal tubule cells drives diabetic renal interstitial fibrogenesis. Diabetes，2020， 69(11): 2446–2457. doi: 10.2337/db20-0579.

ZENI L， NORDEN A G W， CANCARINI G， et al. A more tubulocentric view of diabetic kidney disease. J Nephrol，2017，30(6): 701–717. doi: 10. 1007/s40620-017-0423-9.

FARIAS R S， SILVA-AGUIAR R P， TEIXEIRA D E， et al. Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease. Eur J Pharmacol，2023，942: 175521. doi: 10.1016/j.ejphar.2023.175521.

FURUICHI K， SHIMIZU M， OKADA H， et al. Clinico-pathological features of kidney disease in diabetic cases. Clin Exp Nephrol，2018，22(5): 1046–1051. doi: 10.1007/s10157-018-1556-4.

SHIMIZU M， FURUICHI K， TOYAMA T， et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care，2013，36(11): 3655–3662. doi: 10.2337/dc13-0298.

RODRIGUEZ F， LEE D J， GAD S S， et al. Real-world diagnosis and treatment of diabetic kidney disease. Adv Ther，2021，38(8): 4425–4441. doi: 10.1007/s12325-021-01777-9.

MCGRATH K， EDI R. Diabetic kidney disease: diagnosis, treatment, and prevention. Am Fam Physician，2019，99(12): 751–759.

LI A， YI B， LIU Y， et al. Urinary NGAL and RBP are biomarkers of normoalbuminuric renal insufficiency in type 2 diabetes mellitus. J Immunol Res，2019，2019: 5063089. doi: 10.1155/2019/5063089.

DENG L， LI W， XU G. Update on pathogenesis and diagnosis flow of normoalbuminuric diabetes with renal insufficiency. Eur J Med Res， 2021，26(1): 144. doi: 10.1186/s40001-021-00612-9.

MOLITCH M E， STEFFES M， SUN W， et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care，2010，33(7): 1536–1543. doi: 10.2337/dc09-1098.


Refbacks

  • There are currently no refbacks.